论文部分内容阅读
匹莫苯(pimobendane,UD-CG115 BS,简称PIM)是一种新的具有扩血管作用的非洋地黄类、非儿茶酚胺类强心药,属磷酸二酯酶抑制剂。本文评价PIM对顽固性慢性充血性心衰的短期和长期疗效。方法:11例对地高辛和速尿无效的充血性心衰患者,肺楔压均≥18mmHg。9例病人参加了短期研究,其中7例和另2例参加了为期33～50天的长期研究,(5mg每日2次),前组于口服PIM 5mg前和用药后1、2、3、5、7和9小时分别测有关血流动力学參数,后组于末次剂量后2、3和5小时复查血
Pimobendan (pimobendane, UD-CG115BS, referred to as PIM) is a new vasodilator non-digitalis, non-catecholamine cardiotropic drugs, is a phosphodiesterase inhibitor. This article evaluates the short-term and long-term effects of PIM on refractory chronic congestive heart failure. Methods: Eleven patients with congestive heart failure who did not respond to digoxin and furosemide had a wedge pressure of ≥18 mmHg. Nine patients were enrolled in a short-term study, of which seven and two were enrolled in a long-term study of 33-50 days (5 mg twice daily) before the oral administration of 5 mg PIM and 1, 2, 3, The hemodynamic parameters were measured at 5, 7, and 9 hours, respectively, and the latter group was reexamined at 2, 3, and 5 hours after the last dose